Pharma Business of HIV/AIDS, STDs & STIs

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to increase till $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015. The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, a stringent government regulation for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

    Related Conference of Pharma Business of HIV/AIDS, STDs & STIs

    March 13-14, 2025

    9th International Conference on Rare Diseases

    Prague, Czech Republic
    March 17-18, 2025

    12th International Congress on Infectious Diseases

    Berlin, Germany
    April 14-15, 2025

    15th European Epidemiology and Public Health Congress

    Budapest, Hungary
    June 02-03, 2025

    14th World Congress on Rare Diseases and Orphan Drugs

    Amsterdam, Netherlands
    June 02-03, 2025

    17th Euro-Global Conference on Infectious Diseases

    Amsterdam, Netherlands

    Pharma Business of HIV/AIDS, STDs & STIs Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in